Table 3.
Multivariate analysis of factors predicting seroconversion to trivalent inactivated influenza vaccine in immunocompromised children receiving treatment for cancer
| Variable | H3N2 (A) | H1N1 (A) | B | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Sex | ||||||
| Female | 1 | 1 | 1 | |||
| Male | 0.80 (0.29–2.19) | 0.66 | 2.30 (0.83–6.37) | 0.11 | 0.65 (0.24–1.78) | 0.40 |
| Age | ||||||
| 6 months to <3 years | 1 | 1 | 1 | |||
| 3 to <10 years | 0.92 (0.19–4.42) | 0.91 | 0.36 (0.07–1.73) | 0.20 | 2.41 (0.50–11.59) | 0.27 |
| 10 to <18 years | 2.27 (0.45–11.48) | 0.32 | 0.34 (0.07–1.70) | 0.19 | 4.24 (0.87–20.69) | 0.07 |
| Tumor type | ||||||
| Hematological | 1 | 1 | 1 | |||
| Solid | 7.39 (2.42–22.53) | <0.01 | 2.90 (1.02–8.23) | 0.045 | 3.75 (1.25–11.24) | 0.02 |
| Treatment intensity | ||||||
| High | 1 | 1 | 1 | |||
| Low | 2.81 (1.00–7.89) | 0.049 | 2.36 (0.91–6.09) | 0.08 | 3.16 (1.09–9.18) | 0.03 |
| Lymphocyte count | ||||||
| Low | 1 | 1 | 1 | |||
| Normal range | 1.66 (0.59–4.66) | 0.34 | 1.93 (0.72–5.16) | 0.19 | 2.97 (1.07–8.28) | 0.04 |